Clinical Trials

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

123 enrolled 14 charts

Ovarian Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1 Completed

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Ovarian Neoplasms

NCT04377087 2024-08-20

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Phase 2 Terminated

3 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02282020 2022-07-26

SOLO3

Phase 3 Completed

266 enrolled 31 charts

Ovarian Neoplasms

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

62 enrolled 15 charts

Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3